Search
Cyclophosphamide Treatment Options
A collection of 2185 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
373 - 384 of 2185
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
Recruiting
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa +2 locations
Conditions: Non Hodgkin Lymphoma
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Terminated
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: The University of Alabama at Birmingham (UAB), Birmingham, Alabama +9 locations
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
Active Not Recruiting
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: The University of Chicago, Chicago, Illinois
Conditions: B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Completed
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Stanford Medical Center, Stanford, California
Conditions: B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
Delayed Tolerance Through Mixed Chimerism
Active Not Recruiting
This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Kidney Failure, Kidney Transplant; Complications, Chimera
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
Active Not Recruiting
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Renal Failure
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
Completed
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses. Total marrow irradiation (TMI)/ablative dose radiation therapy is another modality capable of destroying myeloma cells. Autologous peripheral blood/stem cell transplant (ASCT) given after either melphalan or following TMI (aimed at the bone marrow containing areas of the skeleton, the site of origin of myeloma... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
06/04/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Active Not Recruiting
The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients whose leukemia has returned to the bone marrow.
Gender:
ALL
Ages:
26 years and below
Trial Updated:
06/04/2025
Locations: Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Relapsed B-Cell Acute Lymphoblastic Leukemia
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
Active Not Recruiting
This phase II trial studies how well ibrutinib, rituximab, and consolidation chemotherapy consisting of cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, and cytarabine work in treating young patients with newly diagnosed mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the can... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Active Not Recruiting
This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Chemotherapy drugs, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination... Read More
Gender:
ALL
Ages:
Between 3 years and 22 years
Trial Updated:
06/04/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +184 locations
Conditions: Anaplastic Medulloblastoma, Medulloblastoma
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Completed
Background:
- In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient's immune system destroys the donors' cells. Or donor immune cells attack the recipient's tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient and donor have similar human leukocyte antigens (HLA). Researchers want to see if the drug palifermin improves the results of allogeneic SCT from HLA-matched unrelated donors.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma, Myelodysplastic Syndromes
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting
Background:
Chronic granulomatous disease (CGD) affects the immune system. People with CGD are more likely to get infections. Drugs can help control infections, but these treatments can cause side effects including kidney failure and deafness. Stem cell transplants can cure CGD, but these don t always work.
Objective:
To find out if a different drug treatment can improve the success rates of stem cell transplants in people with CGD.
Eligibility:
People aged 4-65 years with CGD.
Design:
Pa... Read More
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
06/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Granulomatous Disease
373 - 384 of 2185